Literature DB >> 2969950

Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

H Hall1, L Farde, G Sedvall.   

Abstract

Affinities and regional densities of the D1- and D2-dopamine receptor subtypes were studied in the human post-mortem brain in vitro using the two selective radioligands 3H-SCH 23390 and 3H-raclopride. 3H-Raclopride binding was confined to the caudate nucleus, the putamen and the substantia nigra, while 3H-SCH 23390 bound to cortical regions as well. The binding of 3H-SCH 23390 was reduced by a low concentration of ketanserin, indicating binding to 5-HT2 receptors in addition to the D1-dopamine receptors. The endogenous neurotransmitter dopamine interacted potently both with the D1-dopamine receptor and the D2-dopamine receptor, displaying two affinity states for each subtype. The distribution of the dopamine receptor subtypes obtained in the present in vitro investigation is in agreement with data obtained with 11C-SCH 23390 and 11C-raclopride in positron emission tomographic studies in human volunteers.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2969950     DOI： 10.1007/bf01244618

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  40 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

3.  Evaluation of a semiautomatic filtration technique for receptor binding studies.

Authors:  H Hall; L Thor
Journal:  Life Sci       Date:  1979-06-11       Impact factor: 5.037

Review 4.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

5.  Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.

Authors:  H Hall; M Sällemark; E Jerning
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-01

6.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

7.  In vivo [3H]spiperone binding to the rat hippocampal formation: involvement of dopamine receptors.

Authors:  S Bischoff; H Bittiger; J Krauss
Journal:  Eur J Pharmacol       Date:  1980-12-05       Impact factor: 4.432

8.  Sulpiride isomers exhibit reversed stereospecificity for D-1 and D-2 dopamine receptors in the CNS.

Authors:  S E Leff; A Chen; I Creese
Journal:  Neuropharmacology       Date:  1984-05       Impact factor: 5.250

Review 9.  Pharmacology of mesocortical dopamine neurons.

Authors:  M J Bannon; R H Roth
Journal:  Pharmacol Rev       Date:  1983-03       Impact factor: 25.468

10.  "Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat.

Authors:  M Amalric; G F Koob; I Creese; N R Swerdlow
Journal:  Life Sci       Date:  1986-11-24       Impact factor: 5.037
View more
  27 in total

1.  [11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography.

Authors:  C Halldin; L Farde; J E Litton; H Hall; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET.

Authors:  G Sedvall; L Farde; A Barnett; H Hall; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Regulation of bat echolocation pulse acoustics by striatal dopamine.

Authors:  Jedediah Tressler; Christine Schwartz; Paul Wellman; Samuel Hughes; Michael Smotherman
Journal:  J Exp Biol       Date:  2011-10-01       Impact factor: 3.312

4.  Dopamine D1 receptors labelled with [3H]SCH23390 in rabbit cerebral cortex and neostriatum. Equilibrium binding, kinetics and selectivity.

Authors:  T A Reader; L Grondin; B Montreuil; K M Dewar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

5.  Brain PET Poster Sessions PP01-M01 to PP02-N07.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

6.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

7.  Quantitative comparison of functional screening by measuring intracellular Ca2+ with radioligand binding at recombinant human dopamine receptors.

Authors:  Matthias U Kassack
Journal:  AAPS PharmSci       Date:  2002

8.  Dopaminergic contributions to hippocampal pathophysiology in schizophrenia: a computational study.

Authors:  Peter J Siekmeier; David P vanMaanen
Journal:  Neuropsychopharmacology       Date:  2014-01-28       Impact factor: 7.853

9.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

10.  Distribution of galanin-binding sites in the monkey and human telencephalon: preliminary observations.

Authors:  C Köhler; A Persson; T Melander; E Theodorsson; G Sedvall; T Hökfelt
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.